04.10.2023 • News

AmbioPharm Appoints Brian Gregg as CEO

Contract development and manufacturing organization (CDMO) AmbioPharm has appointed industry veteran Brian Gregg as CEO. Gregg, who has more than 30 years of experience in the peptide CDMO industry, succeeds Tim Nieters, who will be stepping down after seven years with the company.

Gregg joins AmbioPharm after a 32-year career at Bachem Americas, where he most recently held the position of chief operating officer. He holds an MBA from the San Diego State University, US, and a Bachelor of Arts degree in Chemistry from the US University of California at San Diego.

Juncai (Chris) Bai, Chairman of the Company, said: “We are excited to welcome Brian to our executive team. He has both the leadership experience and necessary background to be immediately effective in growing our business in the U.S. and globally, and we look forward to working with him as we continue to expand on our service offerings and global customer base.”

Source: AmbioPharm
Source: AmbioPharm

Company

Logo:

AmbioPharm, Inc.

1024 Dittman Court
SC 29842 North Augusta
US

Company contact







Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

most read